TICKERNERD
Menu
EMBCEMBCHealthcare · Medical Instruments & Supplies

EMBC Stock Forecast: Embecta Corp. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$5.99
+5.36% on the day

The 4 Wall Street analysts covering Embecta Corp. hold a median 12-month price target of $4 — -33.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 12 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$322.1M
Ticker Nerd rank
84 / 100
Median analyst target
$4.00
Analysts covering
4
Revenue$271.7M−8.1% y/y
Operating income$64.3M
Net income$21.1M
Free cash flow$40.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.9%
1M
+21.3%
YTD
−48.6%
1Y
−53.8%
From 52W high
−57.8%
From 52W low
+107.6%
$3
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EMBC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Embecta Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Issuance
91
Quality
88
Volatility
77
Revisions
66
Accruals
63
Size
58
Growth
32
Momentum
16

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (16): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EMBC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EMBC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26EMBCHigh $5.00Median $4.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
0 Buy3 Hold1 Sell
Low $3.00Median $4.00High $5.00

The green dot is the last close — the median target sits −33.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026B of A SecuritiesMaintainsUnderperform$11 → $3.00
6 May 2026BTIGDowngradeNeutral—
6 May 2026MizuhoMaintainsNeutral—
13 Apr 2026MizuhoMaintainsNeutral—
6 Feb 2026BTIGReiteratesBuy—
5 Sept 2025BTIGReiteratesBuy—
16 July 2025MizuhoMaintainsNeutral—
23 May 2025MizuhoMaintainsNeutral—
10 Apr 2025MizuhoInitiatesNeutral—
27 Nov 2024BTIGUpgradeBuy—
15 July 2024Morgan StanleyMaintainsUnderweight—
10 May 2024Morgan StanleyMaintainsUnderweight—
22 Nov 2023Morgan StanleyMaintainsUnderweight—
18 Oct 2023Morgan StanleyMaintainsUnderweight—
24 Aug 2023Morgan StanleyMaintainsUnderweight—
18 July 2023Morgan StanleyMaintainsUnderweight—
15 May 2023Morgan StanleyMaintainsUnderweight—
6 Jan 2023Morgan StanleyDowngradeUnderweight—
21 Dec 2022Morgan StanleyMaintainsEqual-Weight—
11 Oct 2022Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EMBC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

EMBC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, Embecta Corp. returned −53.8% against +20.4% for the S&P 500, dividends included.

EMBC vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26EMBCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EMBC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+16.9%
Analysts raising
3
Analysts cutting
0
Fundamentals

Embecta Corp. (EMBC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.9×

Cheaper than 67% of US stocks

Price / sales
0.3×

Cheaper than 88% of US stocks

Price / book
−0.5×

Cheaper than 94% of US stocks

EV / EBITDA
5.8×

Cheaper than 51% of US stocks

Growth & margins
Revenue growth (YoY)
−8.1%

Higher than 17% of US stocks

Earnings growth (YoY)
−53.6%

Higher than 10% of US stocks

Gross margin
56.4%

Higher than 69% of US stocks

Operating margin
23.7%

Higher than 83% of US stocks

Net margin
8.6%

Higher than 67% of US stocks

Returns & dividend
Return on equity
−14.6%

Higher than 34% of US stocks

Return on assets
12.2%

Higher than 95% of US stocks

Dividend yield
0.7%

Higher than 68% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Embecta Corp. (EMBC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Embecta Corp. has a market value of $322.1M and an enterprise value of $1.6B.

  • Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter shrank 8.1% year on year.

  • Net income over the same four quarters: $87.5M, a 8.6% net margin.

  • Diluted earnings per share, trailing twelve months: $1.48.

  • Free cash flow in the twelve months to 30 June 2026: $164.6M, after $9.5M of capital spending.

  • Embecta Corp. spent $27.2M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 56.7M.

  • Trailing P/E: 3.9×; forward P/E: 3.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.70%, paying out 31% of earnings.

  • Embecta Corp. employs 1,850 people — $551K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

EMBC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
EMBCEmbecta Corp.$322.1M
84
ZJYLJin Medical International Ltd.$348.0M
14
SMTISanara MedTech, Inc.$323.0M
91
OSUROraSure Technologies, Inc.$271.0M
88
ANGOAngioDynamics, Inc.$469.7M
92
UTMDUtah Medical Products, Inc.$236.9M
78
PDEXPro-Dex, Inc.$201.4M
95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Embecta Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EMBC news & analysis

EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

GlobeNewsWire · 22 Sept 2026negative

Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (NASDAQ: EMBC). The law firm describes itself as a nationally recognized investor rights law firm.

Why it matters — A shareholder investigation into potential fiduciary breaches by Embecta's directors and officers signals possible governance concerns that EMBC watchers would want to track.

EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

GlobeNewsWire · 2 Sept 2026negative

Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. The law firm has issued a shareholder investigation alert regarding the matter.

Why it matters — The investigation signals potential legal or governance scrutiny of Embecta's leadership that shareholders may want to monitor.

embecta to Participate in Investor Events

GlobeNewsWire · 31 Aug 2026neutral

embecta announced it will participate in two investor events in September: the Wells Fargo 2026 Healthcare Conference and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026.

Why it matters — Participation in these healthcare conferences gives EMBC an opportunity to present its business to investors and analysts in the institutional community.

EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

Newsfile Corp · 26 Aug 2026negative

Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (NASDAQ: EMBC). The firm is looking into whether company leadership fulfilled its obligations to shareholders and whether legal remedies may be available.

Why it matters — An investor rights law firm's investigation raises questions about Embecta leadership's conduct and the potential for shareholder legal action.

The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

Seeking Alpha · 25 Aug 2026positive

Seeking Alpha published a bullish analysis of Embecta, describing it as a deep value opportunity with a low price-to-earnings ratio, high free cash flow yield, and strong gross margins despite slightly declining sales and high debt. The article notes positive technical momentum, insider buying, and elevated short interest as potential catalysts for a rebound.

Why it matters — EMBC watchers would care because the analysis highlights the company's defensive medical-products positioning, market leadership, and valuation metrics as potential turnaround signals.

FAQ

Frequently asked questions about EMBC stock

What is the EMBC stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Embecta Corp. have a median 12-month price target of $4, with estimates ranging from $3 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EMBC stock a buy right now?

Of the 4 analysts covering Embecta Corp., 0 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Embecta Corp. 84 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EMBC?

As at 12 Oct 2026, Embecta Corp. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will EMBC stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies -33.2% from the last close, and Ticker Nerd's factor model ranks Embecta Corp. 84 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EMBC stock forecast for 2030?

No analyst covering Embecta Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EMBC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $5 over the next 12 months.

How has EMBC stock performed over the past year?

Embecta Corp. returned -53.8% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Embecta Corp. do?

Embecta Corp. is a medical device company focused on products and services that support diabetes management.

What is the latest news on EMBC?

The most recent item we track (GlobeNewsWire, 22 Sept 2026): "EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty". Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (NASDAQ: EMBC). The law firm describes itself as a nationally recognized investor rights law firm.

Company

About Embecta Corp.

Embecta Corp. is a medical device company focused on products and services that support diabetes management. Embecta Corp. offers a portfolio of pen needles, syringes, safety injection devices, and digital applications designed to help people living with diabetes use insulin and other injectable therapies. The company serves healthcare supply chains through wholesalers and distributors, with products reaching retail and institutional channels in the United States and international markets. Its offerings are used in routine diabetes care and medication delivery, making the company a specialized participant in the broader diabetes care market. Embecta Corp. is headquartered in Parsippany, New Jersey, and operates as a standalone healthcare company centered on essential injection and support solutions for people with diabetes.

CEO Mr. Devdatt Kurdikar Ph.D. · 1,850 employees · United States · https://www.embecta.com